Expert Interview
Examining the recent TRITON3 Phase 3 Clinical Data of Rubraca (rucaparib) from Clovis Oncology for the Treatment of Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations.
Ticker(s): CLVSInstitution: The University of Calgary
- Clinical Associate Professor, Departments of Surgery and Oncology, The University of Calgary Medical Director, Clinic for Advanced and Metastatic Prostate Cancer (CAMP), Prostate Cancer Centre.
- Manages 50 patients with mCRPC and 400 patients with bladder cancer.
- Specializes in the management of prostate, bladder, and kidney cancer and has expertise in open, laparoscopic, and robotic surgical techniques; sits on the Medical Advisory Board for Kidney Cancer Canada and Bladder Cancer Canada.
Roughly how many patients with mCRPC do you manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Rubraca in treating mCRPC?
Added By: c_adminWhat was your high level view of the results announced for TRITON-3?
What were the strengths and weaknesses of the TRITON-3 trial?
In the setting of post-AR directed therapy (either abiraterone, enzalutamide, apalutamide, or investigational agent in this trial) what is the current standard of care?
Added By: user1ae2bf5fHow do you view a comparison with a physician's choice of docetaxel, abiraterone, or enzalutamide?
Added By: user1ae2bf5fThere was a protocol amendment that allowed patients with prior AR-targeted therapy in hormone sensitive setting to qualify for the trial.
Could you explain the significance of this? How might this change the result or add context to it?
18% of patients in TRITON3 had received prior AR-targeted therapy in the metastatic hormone-sensitive setting only.
How commonly is the genetic testing done for prostate cancer patients to determine if they have the BRCA mutations?
Is this practice changing at all. Given that this was a confirmatory trial and they previously had accelerated approval in this setting, were u already using it in this patient population?
How will this confirmatory result impact your prescribing?
How might this compete in the post-AR setting against PSMA radionuclide therapies where there has been early data and there will be trial readouts soon?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
